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Introduction: Although neuropsychiatric systemic lupus erythematosus (NPSLE) is one of the recalcitrant
complications of the disease, its pathogenesis still remains unclear. Previous studies revealed that antibodies
reactive with NMDA (N-methyl-D-aspartate) receptor NR2 (anti-NR2) are elevated in cerebrospinal fluid (CSF) of
patients with diffuse psychiatric/neuropsychological syndromes (diffuse NPSLE), which is usually more recalcitrant
than neurologic syndromes of NPSLE (focal NPSLE). Two mechanisms have been implicated for the elevation of CSF
IgG, including intrathecal synthesis and transudation through the damaged blood-brain barrier (BBB). The present
study was designed in order to elucidate the roles of BBB function and intrathecal synthesis of anti-NR2 in the
elevation of CSF anti-NR2 with regard to the severity in NPSLE.
Methods: Paired serum and CSF samples were obtained from 81 systemic lupus erythematosus (SLE) patients when
they presented active neuropsychiatric manifestations, and from 22 non-SLE control patients with non-inflammatory
neurological diseases. The 81 SLE patients consisted of 55 patients with diffuse NPSLE, including 23 patients with
acute confusional state (ACS), the severest form of diffuse NPSLE, and 26 patients with neurologic syndromes or
peripheral nervous system involvement (focal NPSLE). IgG anti-NR2 and albumin were measured by ELISA. BBB
function and intrathecal synthesis of anti-NR2 were evaluated by Q albumin and by CSF anti-NR2 index,
respectively.
Results: CSF anti-NR2 levels, Q albumin and CSF anti-NR2 index were significantly higher in NPSLE than in non-SLE
control. CSF anti-NR2 levels and Q albumin were significantly higher in ACS than in non-ACS diffuse NPSLE (anxiety
disorder, cognitive dysfunction, mood disorder and psychosis) or in focal NPSLE, whereas there was no significant
difference in CSF anti-NR2 index among the 3 groups. CSF anti-NR2 levels were significantly correlated with
Q albumin in diffuse NPSLE (r = 0.3754, P = 0.0053).
Conclusions: These results demonstrate that the severity of BBB damages plays a crucial role in the development
of ACS, the severest form of diffuse NPSLE, through the accelerated entry of larger amounts of anti-NR2 into the
central nervous system.* Correspondence: shunsei_tenpoint@yahoo.co.jp
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Neuropsychiatric systemic lupus erythematosus (NPSLE)
is one of the recalcitrant complications of the disease,
leading to substantial impairment of quality of life as well
as disability [1,2]. Among a variety of manifestations in
NPSLE, acute confusional state (ACS) in diffuse psy-
chiatric/neuropsychological syndromes (diffuse NPSLE) is
the most serious, requiring extensive immunosuppressive
therapy and sometimes resulting in poor prognosis [3,4].
Several studies have demonstrated that IL-6 in cerebro-
spinal fluid (CSF) is elevated in patients with NPSLE, in-
cluding those with diffuse NPSLE and focal NPSLE [5,6].
Among various cytokines, IL-6 and chemokines, but not
Th1/Th2 cytokines, were found to be significantly elevated
in NPSLE [7,8]. Notably, a multicenter retrospective study
with SLE patients who showed psychiatric manifestations
demonstrated that the sensitivity and specificity of CSF
IL-6 for diffuse NPSLE were 87.5% and 92.3%, respectively
[9]. CSF IL-6 appeared to be elevated independently of
serum IL-6 [5,9]. It was also found that CSF IL-6 was not
correlated with specific blood abnormalities, CSF cell
counts, or abnormalities identified on brain magnetic re-
sonance imaging and electroencephalography [10]. Thus,
the mechanism of the elevation of IL-6 in CSF remains
unclear.
On the other hand, previous studies showed that auto-
antibodies against neuronal cells were specifically elevated
in CSF from patients with diffuse NPSLE [11,12]. Several
antigens have been implicated for the candidates of the
targets of autoantibodies against neuronal cells, including
ribosomal P proteins [13]. Of note, recent studies have
demonstrated that CSF antibodies reactive with N-me-
thyl-D-aspartate (NMDA) receptor NR2 subunit on neu-
ronal cells (anti-NR2) are associated with diffuse NPSLE
[14-16]. However, neither the precise mechanism of the
elevation of CSF anti-NR2 nor its relevance with the se-
verity of diffuse NPSLE is understood.
Two mechanisms have been implicated for the eleva-
tion of CSF IgG, including intrathecal synthesis and
transudation through the damaged blood-brain barrier
(BBB) (more strictly, the blood-CSF barrier) [17-19].
Since intrathecal IgG production has been shown to be
elevated in NPSLE [18,20], it is likely that intrathecal
production of anti-NR2 might be enhanced in diffuse
NPSLE. On the other hand, it is also possible that tran-
sudation of anti-NR2 through the damaged BBB might
contribute to the elevation of anti-NR2 in CSF. However,
the nature of the integrity of the BBB in NPSLE has not
been fully delineated. The current studies examined the
BBB function and intrathecal synthesis of anti-NR2 in
relation to the severity of diffuse NPSLE. It should be
pointed out that BBB refers to the morphological basis
for restriction of protein entry from the systemic circula-
tion into the brain tissue, particularly through the braincapillary walls [19]. As albumin is produced exclusively
in the liver, the increase of albumin in CSF is considered
to reflect damage of the BBB. Thus, the albumin CSF/
serum concentration ratio, called Q albumin, is widely
accepted as an indicator of BBB function [17,19].
Methods
Patients and samples
Eighty-one patients with SLE were included in the present
study. All patients fulfilled the American College of
Rheumatology (ACR) 1982 revised criteria for the classifi-
cation of systemic lupus erythematosus (SLE) [21]. Of the
81 SLE patients, 55 had diffuse psychiatric/neuropsycho-
logical syndromes (diffuse NPSLE) according to the 1999
ACR definition of NPSLE [3], whereas 26 patients had
neuropsychiatric manifestations other than diffuse NPSLE,
including neurologic syndromes and peripheral nervous
system involvement (focal NPSLE) (Table 1). Among the
55 patients with diffuse NPSLE, 23 patients had complica-
tions due to acute confusional state (ACS), the severest
form of diffuse NPSLE [3]. All the patients with NPSLE
were hospitalized in Teikyo University Hospital or other
correlated hospitals between 1993 and 2007. In addition,
22 patients with non-SLE non-inflammatory neurologic
diseases (8 with cervical spondylosis, 7 with cerebrovas-
cular disease, 3 with neurodegenerative disease, two with
hyperventilation syndrome, 1 with headache, and 1 with
diabetic neuropathy) were studied as non-SLE controls.
All the 103 patients gave informed consent, and the study
was approved by the institutional ethical committee of
Teikyo University School of Medicine. CSF specimens
were obtained from the patients by a lumbar puncture on
the same day that serum samples were obtained, when the
diagnosis of NPSLE was made by neurologists and rheu-
matologists. These samples were kept frozen at -30°C until
they were assayed. All assays were performed without
knowledge of the diagnosis or clinical presentations. Fur-
thermore, upon entering the present study, the diagnosis
of the 81 patients with NPSLE and its classification was
reconfirmed by hospital case records.
Measurement of albumin
Albumin in CSF and sera was measured by ELISA using
Human Albumin ELISA Quantitation Set (Bethyl Labora-
tories, Montgomery, Tx, USA).
Evaluation of BBB function and intrathecal synthesis of
anti-NR2
BBB function and intrathecal synthesis of anti-NR2 were
evaluated by Q albumin (CSF albumin × 1,000/serum
albumin) and by CSF anti-NR2 index ((CSF anti-NR2 ×
serum albumin)/(serum anti-NR2 × CSF albumin)), re-
spectively, as previously described [17-19].








Diffuse neuropsychiatric-SLE 55 6/49 37.0 ± 14.2












Non-SLE control 22 21/1 48.0 ± 13.7
*Two patients also presented mood disorder.
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aspartate (NMDA) receptor subunit NR2
Anti-NR2 in sera and CSF were determined by specific
ELISA using the highly purified synthetic 10 amino-acid
peptide DWEYSVWLSN [22], conjugated to human
serum albumin (HSA) as previously described [14]. The
concentration of anti-NR2 that produced half of the
maximal absorbance at 492 nm, given by saturating con-
centrations of anti-NR2 in the ELISA plate, was arbitra-
rily defined as 1 U/ml. The specific anti-NR2 activitiesFigure 1 Cerebrospinal fluid (CSF) antibodies to the N-methyl-D-aspa
systemic lupus erythematosus (NPSLE). (A) Comparison between NPSLE
NPSLE. ACS, acute confusional state; Non-ACS, diffuse NPSLE other than AC
and psychosis; Focal, focal NPSLE. Statistical analysis was performed by the
multiple comparison test (B).were determined by subtracting the values for the non-
specific binding activity to HSA from those for binding
activity to NR2 peptide-HSA conjugates [14].
Measurement of IL-6 and anti-ribosomal P
CSF IL-6 was measured by bioassay using IL-6-dependent
cell line MH60.BSF2 [5]. Serum anti-ribosomal P was de-
termined by ELISA using purified bovine ribosomal P pro-
teins (Arotec, Wellington, New Zealand), as previously
described [13].
Statistical analysis
Differences in various parameters between control and
NPSLE or among various groups of NPSLE were analyzed
by the Mann-Whitney U-test or the Kruskal-Wallis test
with the Dunn multiple comparison test, respectively,
using GraphPad Prism 6 for Mac OS X ver. 6.0b, Graph-
Pad Software, Inc., San Diego, CA, USA. Correlation bet-
ween various parameters was examined by the Spearman
rank correlation test.
Results
CSF anti-NR2 are correlated with the severity of NPSLE
Initial experiments compared CSF anti-NR2 levels in
various groups. As shown in Figure 1A, CSF anti-NR2
levels were significantly elevated in NPSLE compared
with the non-SLE control group. NPSLE consists of focal
NPSLE and diffuse NPSLE, including ACS or non-ACS
(anxiety disorder, cognitive dysfunction, mood disorder
and psychosis). CSF anti-NR2 levels were significantly
elevated in ACS diffuse NPSLE compared with those in
focal NPSLE and in non-ACS diffuse NPSLE (Figure 1B).
CSF anti-NR2 levels appeared to be higher in non-ACS
diffuse NPSLE than those in focal NPSLE, although itrtate (NMDA) receptor subunit NR2 (anti-NR2) in neuropsychiatric
and non-SLE controls, (B) comparison among various subtypes of
S, including anxiety disorder, cognitive dysfunction, mood disorder
Mann-Whitney U-test (A) and the Kruskal-Wallis test with the Dunn
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dicate that CSF anti-NR2 levels are correlated with the
severity of NPSLE in terms of ACS.
It is pointed out that psychosis is sometimes presented
as a severe manifestation [3]. However, CSF anti-NR2
levels in eight patients with psychosis (0.145 ± 0.047 U/ml
(mean ± SD)) were not significantly different from those
in 24 patients with non-ACS non-psychosis diffuse NPSLE
(0.271 ± 0.053 U/ml) (P = 0.3728 as evaluated by the
Mann-Whitney U-test).
Intrathecal anti-NR2 synthesis and BBB function in each
subset of NPSLE
We next examined intrathecal anti-NR2 synthesis and
BBB function in various subsets of NPSLE, including
ACS, non-ACS diffuse NPSLE and focal NPSLE, in order
to delineate the mechanism of elevation of CSF anti-
NR2. As shown in Figure 2, CSF anti-NR2 index, an
indicator of intrathecal anti-NR2 production, was signifi-
cantly elevated in NPSLE compared with the non-SLE
control group. However, there were no significant dif-
ferences in CSF anti-NR2 index among the three groups
of NPSLE, including focal NPSLE, ACS and non-ACS
diffuse NPSLE. These results indicate that the elevation
of intrathecal synthesis of anti-NR2 is enhanced in
NPSLE irrespective of the category or the severity.
On the other hand, Q albumin was also significantly
elevated in NPSLE compared with in non-SLE control
group (Figure 3). More importantly, Q albumin was
higher in ACS than in focal NPSLE or in non-ACS diffuse
NPSLE. Moreover, there was no significant difference in Q
albumin between focal NPSLE and non-ACS diffuse
NPSLE. Accordingly, when compared with non-SLE con-
trol group, Q albumin was not significantly elevated either
in non-ACS diffuse NPSLE or in focal NPSLE. Finally,
CSF anti-NR2 was significantly correlated with Q albuminFigure 2 Intrathecal synthesis of anti-NR2 (CSF anti-NR2 index) in neuro
between NPSLE and non-SLE control, (B) comparison among various subty
other than ACS, including anxiety disorder, cognitive dysfunction, mood di
performed by the Mann-Whitney U-test (A) and by the Kruskal-Wallis test win patients with diffuse NPSLE (ACS and non-ACS)
(Figure 4). The results indicate that BBB damages take
place in NPSLE. Moreover, the data also support the con-
clusion that BBB damage plays an important role in the
pathogenesis of ACS, the severest form of diffuse NPSLE,
allowing the entry of a larger amount of anti-NR2 from
the systemic circulation into the brain.
Discussion
NMDA receptors are a subgroup of the glutamate recep-
tor family, responsible for the majority of excitatory syn-
aptic transmission in the central nervous system [23,24].
DeGiorgio et al. showed that injection of anti-NR2 glu-
tamate receptor binding antibodies (purified antibodies
from the sera of SLE patients or one CSF sample from an
SLE patient with progressive cognitive decline) into the
mouse brain resulted in apoptosis of the neuronal cells
without signs of inflammation [22]. Of note, Kowal et al.
have recently demonstrated that mice induced by antigen
to express anti-NR2 have no neuronal damage until break-
down of the BBB takes place [25]. Presumably, an intact
BBB prevented the transport of anti-NR2 from the sys-
temic circulation into the brain [25]. Previous studies have
disclosed that CSF anti-NR2 is elevated in diffuse NPSLE
compared with that in focal NPSLE or in non-SLE con-
trols [14]. In the present study, we have demonstrated that
CSF anti-NR2 levels were the highest in ACS, the severest
form of diffuse NPSLE, among various types of NPSLE. In
fact, the effect of anti-NR2 antibodies on neurons has
been shown to be dose dependent [26]. Thus, at low con-
centrations they alter synaptic function, whereas at higher
concentrations they can cause neuronal cell death by
apoptosis [26]. It is therefore suggested that the presence
of higher concentrations of anti-NR2 within the central
nervous system might result in greater neuronal damage,
leading to the development of ACS.psychiatric systemic lupus erythematosus (NPSLE). (A) Comparison
pes of NPSLE. ACS, acute confusional state; Non-ACS, diffuse NPSLE
sorder and psychosis; Focal, focal NPSLE. Statistical analysis was
ith the Dunn multiple comparison test (B).
Figure 3 Blood-brain barrier functions (Q albumin) in neuropsychiatric systemic lupus erythematosus (NPSLE). (A) Comparison between
NPSLE and non-SLE control, (B) comparison among various subtypes of NPSLE. ACS, acute confusional state; Non-ACS, diffuse NPSLE other than
ACS, including anxiety disorder, cognitive dysfunction, mood disorder and psychosis; Focal, focal NPSLE. Statistical analysis was performed by the
Mann-Whitney U-test (A) and the Kruskal-Wallis test with the Dunn multiple comparison test (B).
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group is heterogeneous for a relatively small group.
However, it is uniform in that they all belong to non-
inflammatory diseases in which no immunological ab-
normalities are involved [20]. Another limitation of our
study is that samples were collected for long terms of
about 15 years and stored at -30°C. It would have been
better to preserve samples at lower temperatures as low
as -80°C in order to avoid protein degradation.
Two mechanisms have been implicated for the eleva-
tion of CSF IgG. One is transudation through the dam-
aged BBB from the systemic circulation, and the other is
intrathecal synthesis [17,19]. Previous studies disclosed
that CSF IgG index, an indicator of intrathecal IgG syn-
thesis, is elevated in NPSLE [18,20]. Accordingly, CSF
anti-NR2 index was elevated in diffuse NPSLE compared
with that in non-SLE control in the present study. How-
ever, there were no significant differences in CSF anti-Figure 4 Correlation between cerebrospinal fluid (CSF) anti-
NR2 and Q albumin in patients with diffuse neuropsychiatric
systemic lupus erythematosus (NPSLE). Statistical significance was
analyzed by the Spearman rank correlation test.NR2 index between ACS and non-ACS diffuse NPSLE.
Therefore, the elevation of CSF anti-NR2 levels in ACS
compared with that in non-ACS diffuse NPSLE cannot
be accounted for by the increased intrathecal synthesis
of anti-NR2. It should be underscored that the elevation
of CSF IgG index was not confined to diffuse NPSLE
[18,20]. Thus, it is conceivable that CSF IgG index might
be elevated in focal NPSLE as well as in ACS and non-
ACS NPSLE in our series of patients. Of note, patients
with higher CSF IgG index showed CSF oligoclonal IgG
bands [18,19]. Again, the presence of CSF oligoclonal
IgG bands was not confined to diffuse NPSLE [18].
Taken together, it is strongly suggests that the enhanced
intrathecal IgG production might not be specific for dif-
fuse NPSLE, but a may be a common feature in NPSLE.
BBB function has been evaluated by Q albumin, because
albumin is produced exclusively in the liver and its pres-
ence in CSF is totally dependent on its transudation from
the systemic circulation [17,19]. Q albumin values in most
patients with NPSLE were found to be below 9.0, the
upper normal value of control subjects [18,20]. However,
it has not been clarified whether there might be any differ-
ence in Q albumin among various types of NPSLE. The
results in the present study have disclosed that Q albumin
was significantly elevated in NPSLE compared with that in
non-SLE controls. More importantly, Q albumin was
shown to be apparently higher in ACS than in non-ACS
diffuse NPSLE or in focal NPSLE. By contrast, there was
no significant difference in Q albumin between non-ACS
diffuse NPSLE and focal NPSLE. The data thus indicate
that the damage in BBB is a critical factor for the develop-
ment of ACS. Thus, since there was no significant diffe-
rence in serum anti-NR2 levels among the 3 groups of
NPSLE (data not shown), the damage in BBB is consi-
dered to play a critical role in the elevation of CSF anti-
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nificantly correlated with Q albumin in diffuse NPSLE
(ACS and non-ACS) in the present study.
A number of studies have revealed that CSF IL-6 is
elevated in patients with NPSLE, and is useful for its
diagnosis [5-10]. However, the mechanism of the eleva-
tion of CSF IL-6 has not been clarified. Notably, CSF
IL-6 was also most markedly elevated in ACS, where
CSF anti-NR2 levels were the highest (data not shown).
Recent studies have shown that anti-NR2 binds the sur-
face of endothelial cells and enhances their production
of proinflammatory cytokines, IL-6 and IL-8, through
activation of NFkB [27]. On the other hand, it should be
noted that the expression of mRNA for IL-6 was shown
to be enhanced in granular neurons in the hippocampus
of an SLE patient with diffuse NPSLE [28]. Therefore, it
is suggested that interactions of neuronal cells with
neuron-reactive autoantibodies, such as anti-NR2, might
involve the production of IL-6 by neuronal cells. Further
studies are required to confirm this point.
The mechanism of BBB damage in ACS remains to be
elucidated. It should be pointed out that anti-ribosomal
P enhances the capacity of activated human monocytes
to produce IL-6, TNF-α and vascular endothelial growth
factor [29,30], which can alter the integrity of the BBB
[31-34]. However, neither serum anti-NR2 nor serum
anti-ribosomal P was correlated with Q albumin in our
series of patients (data not shown). As a variety of auto-
antibodies are expressed in SLE, it is possible that there
might be such autoantibodies other than anti-NR2 or
anti-ribosomal P that might cause damage to the BBB.
Further studies would be required to identify the whole
spectrum of autoantibodies that might cause BBB
damage.
Conclusion
The current studies examined the BBB function and intra-
thecal synthesis of anti-NR2 in relation to the severity of
diffuse NPSLE. CSF anti-NR2 levels and Q albumin were
significantly higher in ACS than in non-ACS diffuse
NPSLE (anxiety disorder, cognitive dysfunction, mood
disorder and psychosis) or in focal NPSLE, whereas there
was no significant difference in CSF anti-NR2 index
among the three groups. CSF anti-NR2 levels were signifi-
cantly correlated with Q albumin in diffuse NPSLE. These
results support the conclusion that the severity of BBB
damages plays a crucial role in the development of ACS,
the severest form of diffuse NPSLE, through the accele-
rated entry of larger amounts of anti-NR2 into the central
nervous system.
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